Research programme: adult stem cell therapeutics - TiGenix

Drug Profile

Research programme: adult stem cell therapeutics - TiGenix

Alternative Names: Cx 602; Cx 603

Latest Information Update: 22 Dec 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellerix
  • Developer TiGenix
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 22 Dec 2011 Preclinical development is ongoing in Spain
  • 25 Aug 2011 Ethical committee of Clínica Univerditaria de Navarra (Spain) approves phase I trial for Cx 621 in Autoimmune disorders
  • 18 Jul 2011 Preclinical trials in Osteoarthritis in Spain (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top